Why Cosmetic Injectable Prescriptions Should Not Be Treated as 12 Month Repeat Scripts in Australia

The central compliance position is that even where a prescription may remain legally capable of supply or administration for up to 12 months under some state prescribing frameworks, cosmetic injectable prescribing is not properly considered as a repeat-script model analogous to long-term chronic disease prescribing.

In Australian cosmetic medicine, the compliance question is no longer whether telehealth cosmetic prescribing is possible. It plainly is. The more important question is whether a prescribing model is clinically defensible, consultation-specific, and aligned with the increasingly explicit expectations of Ahpra, the Medical Board of Australia, the Nursing and Midwifery Board of Australia, the TGA, and jurisdictional drugs and poisons frameworks. This article focuses on prescription-only cosmetic injectables, especially Schedule 4 cosmetic prescribing pathways, rather than every cosmetic injectable product category in the market. [1][2][3][4][6][13][14] 

In cosmetic medicine, treatment goals, facial anatomy, prior treatment effects, patient expectations, and the exact procedure being contemplated can all change between visits. For that reason, a fresh medical assessment and, where the prescriber is not physically present, a contemporaneous video consultation for cosmetic injectables is identified as the stronger and more defensible compliance position at every treatment appointment.[3][4][7] 

The regulatory baseline in Australia

For medical practitioners, the starting point is unusually clear. The Medical Board of Australia’s cosmetic procedures guideline states that medical practitioners must have a consultation with the patient, either in person or by video, each time they prescribe Schedule 4 cosmetic injectables.

The same guideline also requires the prescribing doctor, or their delegate, such as the treating nurse, to assess suitability, explore motivations and expectations, consider alternatives, decline treatment if it is not in the patient’s best interests, obtain informed consent, and ensure responsibility for patient management and post-procedure care, including where another registered practitioner administers the injectable.[3][6]

Since 2 September 2025, the broader multiprofession Ahpra and National Boards guideline for non-surgical cosmetic procedures has reinforced the same direction for non-medical registered health practitioners who are authorised prescribers. It requires an evidence-based, holistic assessment of the person, discussion of motivations and expectations, consideration of underlying psychological issues including body dysmorphic disorder, and either an in-person or video consultation by the authorised prescriber, or where permitted, their delegate, each time a cosmetic injectable is prescribed.[4][5][6]

The joint Ahpra, Medical, Nursing and Midwifery, and Pharmacy Board statement on prescribing and dispensing medicines sharpens the governance message. It warns against health service models designed to provide access to a predetermined medicine and raises concern with prescribing models that create a long tail of medicine use, where the clinical purpose, timing and circumstances of later use may become unclear in the absence of further prescriber touch points. In that context, the statement supports a model of real-time prescribing each time a new clinical episode of care arises, including where the concern is aesthetic rather than therapeutic. It also stresses that the prescribing practitioner remains responsible for safe and appropriate care regardless of the business model used.[1][7] 

The TGA’s guidance is consistent with that patient-safety framing. Its cosmetic injections checklist states that the products used in cosmetic injections require a valid prescription from an authorised prescriber and that the prescriber or the treating Nurse must consult with the patient and fully explain the procedure before it goes ahead, either face to face or by video conference.[13][14] 

Why cosmetic medicine is not repeat-script medicine

This is where cosmetic prescribing Australia departs sharply from static therapeutic models. In chronic disease management, prescribing commonly follows relatively stable therapeutic endpoints that can be trended over time: HbA1c targets in type 2 diabetes, blood pressure targets, and cardiovascular risk categories. Those models are still personalised, but they are typically anchored to measurable physiological objectives and longitudinal maintenance strategies.[25][26][27] 

Cosmetic injectable prescribing is different in kind, not just degree. The relevant Ahpra and Medical Board guidance does not frame cosmetic injectables as an automatically recurring intervention. Instead, it requires the practitioner to reassess why the patient wants the procedure, whether expectations remain realistic, whether there are psychological contraindications, what alternative options exist, and whether the procedure is appropriate at that point in time. Those are inherently dynamic questions, especially in a field defined by subjective aesthetic goals, visible asymmetry, ageing, prior treatments, complications, and changing patient preference.[3][4] 

The consent obligations also point in the same direction. For cosmetic injectables, patients must be given enough information to make an informed decision, including what the procedure involves, which injectable is being prescribed or used, the type and quantity, the possible short and long term outcomes, patient-specific risks, and the possibility of further treatment such as hyaluronidase, antibiotics, or later revision care. That is not the language of a passive repeat medicine model. It is the language of consultation-specific decision-making tied to the exact procedure in contemplation at that visit.[3][4][22] 

In practical terms, the clinical landscape in cosmetic medicine moves every time treatment occurs. Prior botulinum toxin may alter muscle movement and balance. Previous filler may change contour, tissue behaviour, and risk. The proposed treatment area, product selection, dosage, and injection pattern may differ materially from the last appointment. A prescription written months earlier may still exist in a legal sense, but that does not mean it accurately authorises the procedure that is about to be performed now. That conclusion is not an express legislative rule. It is a professionally grounded inference from the regulatory emphasis on contemporaneous assessment, informed consent, suitability, and documentation in cosmetic medicine.[3][4][7] 

Why a contemporaneous video consultation may be required at each appointment

In several jurisdictions, ordinary Schedule 4 prescriptions may remain valid for up to 12 months from the date written. NSW Health states that prescriptions are generally valid for 6 months from issue, subject to exceptions. Queensland Health states that prescriptions for S2, S3 and S4 medicines are valid for 12 months, including prescriptions for administration. WA guidance similarly states that Schedule 4 prescriptions expire 12 months after issue. But that is a dispensing and legal validity concept. It does not displace the professional requirement in cosmetic medicine to reassess the patient and prescribe appropriately for the actual treatment being authorised.[15][16][17][19] The conclusion that legal validity does not equal clinical defensibility in cosmetic injectables is an inference drawn from reading those rules alongside the Board guidelines.[2][3][4] 

That distinction matters most in nurse injector compliance and remote prescribing models. A real-time video consultation is approved and often a defensible modality because the doctor or authorised prescriber or their delegate may need to observe current facial appearance, asymmetry, movement, skin or tissue changes, and the patient’s present treatment objectives. The telehealth guidance does not say video is mandatory in every telehealth consultation. What it does say is that telehealth must be clinically appropriate and meet the same standard as in-person care as far as possible, and that practitioners must arrange an in-person review when telehealth alone is not appropriate. In cosmetic medicine, that makes video markedly more supportable than telephone for most fresh prescribing decisions.[2][6][13] 

This is also why one blanket prescription intended to cover repeated cosmetic injectable use over a 12 month period sits incompatibly with cosmetic telehealth compliance. The regulator’s focus is not on maximising the lifespan of a script. It is on whether the practitioner and their delegate has undertaken a proper real-time assessment, authorised an appropriate medicine for that particular person and that particular episode of care. In a specialty where each visit may involve different treatment areas, changing dose requirements, different product choices, or a decision not to treat, a consultation-specific prescription is, based on current regulation, the compliance position.[3][4][8][9][10] 

What defensible cosmetic injectable prescribing looks like

A defensible cosmetic injectable prescribing model starts by separating what legislation requires from what best-practice governance should add. Prescription rules in official state guidance require core particulars such as the medicine name, form or formulation, strength, precise directions for use, dosage or amount, quantity, repeats if any, date, patient details and prescriber details. NSW Health also states that the decision whether to prescribe a scheduled medicine, and the choice of medicine, form, strength and quantity, must be made by the prescriber and not by patient request.[15][17][18] 

For cosmetic medicine, given the elective and discretionary nature of the service, governance often goes further. As a matter of cosmetic injectables compliance, a consultation-specific authorisation should identify the exact medicine and, where clinically relevant, the exact brand or formulation, authorised dosage or units, anatomical treatment area, intended use or aesthetic objective, relevant administration directions, clinically important limitations, and the review or treatment interval being contemplated. The first part of that list is supported directly by prescription law. The second part follows from the Boards’ requirements for informed consent, patient-specific consultation and prescribing, and records detailed enough for another practitioner to understand exactly what was authorised and performed.[3][4][17][18][20][21]

For nurse injector compliance, the governance burden is not merely administrative. In practical terms, much of the front-line responsibility for consultation, consent, assessment, documentation and procedural compliance sits with the nurse injector because they are the direct clinical interface with the patient. The 2025 cosmetic procedure guideline places the patient suitability assessment with registered nurses or nurse practitioners. Where formal arrangements allocate post-procedure care to the nurse injector, the nurse becomes the responsible point of care for patient assessment, treatment readiness, procedural compliance, post-treatment monitoring, escalation, and continuity of care when the prescriber is not personally available. The NMBA standards reinforce that registered nurses are accountable for comprehensive assessment, planning, evaluation, delegation and supervision, while enrolled nurses work under registered nurse supervision. In that context, the nurse injector should understand that the immediate compliance burden and clinical risk sit with them first, particularly where they are assessing the patient, confirming consent, administering the medicine, documenting the treatment and managing escalation at the point of care.[4][8][9][10][11][12] 

For clinics, the governance implication is straightforward. Clinics utilise Yooli as a compliance platform because its workflows are designed around the requirements that apply to cosmetic injector compliance. By default, Yooli supports consultation and scripting processes that align with applicable laws, regulations and professional guidelines, rather than relying on shortcut prescribing models, text-based S4 cosmetic prescribing, or broad authorisations later stretched across multiple aesthetic visits. Its operational architecture is built to support real-time consultation, consultation-specific prescribing, structured consent, documented treatment planning, clear accountability between prescriber and injector, accessible records, and post-procedure escalation pathways. In practical terms, Yooli places regulatory guardrails inside the clinical workflow, supporting a model that is more consistent with current cosmetic medicine regulations in Australia and with defensible clinical practice.[3][4][6][7][23][24] 

Conclusion

The strongest Australian regulatory point is no longer merely implied. For doctors, the Medical Board already says there must be an in-person or video consultation each time Schedule 4 cosmetic injectables are prescribed. For other registered prescribers in non-surgical cosmetics, the 2025 Ahpra guideline adopts the same logic and expressly rejects asynchronous prescribing by text or email. Read alongside telehealth guidance, informed consent requirements, documentation standards and prescriber responsibility for patient management, the compliance direction is clear in that cosmetic injectable prescribing should be highly individualised, real-time, and tied to the exact treatment being authorised at that appointment.[2][3][4][6][7] 

References

1. Medical Board of Australia. Good medical practice: a code of conduct for doctors in Australia. Medical Board of Australia. URL: https://www.medicalboard.gov.au/Codes-Guidelines-Policies/Code-of-conduct.aspx
2. Medical Board of Australia. Guidelines: Telehealth consultations with patients. Approved 24 May 2023, effective 1 September 2023. URL: https://www.medicalboard.gov.au/Codes-Guidelines-Policies/Telehealth-consultations-with-patients.aspx
3. Medical Board of Australia. Guidelines for registered medical practitioners who perform cosmetic surgery and procedures. Approved 22 February 2023, effective 1 July 2023. URL: https://www.medicalboard.gov.au/Codes-Guidelines-Policies/Cosmetic-medical-and-surgical-procedures-guidelines.aspx
4. Australian Health Practitioner Regulation Agency and National Boards. Guidelines for registered health practitioners who perform non-surgical cosmetic procedures. Effective 2 September 2025. URL: https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Cosmetic-procedure-guidelines.aspx
5. Australian Health Practitioner Regulation Agency. Resources for performing non-surgical cosmetic procedures. Effective from 2 September 2025. URL: https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Cosmetic-procedure-guidelines/Resources-for-performing-non-surgical-cosmetic-procedures.aspx
6. Australian Health Practitioner Regulation Agency. Information for practitioners who provide virtual care. Page reviewed 7 October 2025. URL: https://www.ahpra.gov.au/Resources/Information-for-practitioners-who-provide-virtual-care.aspx
7. Ahpra, Medical Board of Australia, Nursing and Midwifery Board of Australia, and Pharmacy Board of Australia. Joint statement on professional responsibilities for prescribing and dispensing medicines. Approved 29 May 2024, effective 3 June 2024. URL: https://www.ahpra.gov.au/documents/default.aspx?chksum=evycoF3swGNGFdZQsS%2BgaQ%3D%3D&dbid=AP&record=WD24%2F33726
8. Nursing and Midwifery Board of Australia. Information for nurses who perform non-surgical cosmetic procedures. 5 June 2025. URL: https://www.nursingmidwiferyboard.gov.au/Codes-Guidelines-Statements/Codes-Guidelines/Information-for-nurses-who-perform-nonsurgical-cosmetic-procedures.aspx
9. Nursing and Midwifery Board of Australia. Registered nurse standards for practice. Effective 1 June 2016. URL: https://www.nursingmidwiferyboard.gov.au/codes-guidelines-statements/professional-standards/registered-nurse-standards-for-practice.aspx
10. Nursing and Midwifery Board of Australia. Nurse practitioner standards for practice. Effective 1 March 2021. URL: https://www.nursingmidwiferyboard.gov.au/codes-guidelines-statements/professional-standards/nurse-practitioner-standards-of-practice.aspx
11. Nursing and Midwifery Board of Australia. Fact sheet: Scope of practice and capabilities of nurses. Updated May 2024. URL: https://www.nursingmidwiferyboard.gov.au/Codes-Guidelines-Statements/FAQ/Fact-sheet-scope-of-practice-and-capabilities-of-nurses.aspx
12. Nursing and Midwifery Board of Australia. Fact sheet: Enrolled nurse standards for practice. URL: https://www.nursingmidwiferyboard.gov.au/Codes-Guidelines-Statements/FAQ/Enrolled-nurse-standards-for-practice
13. Therapeutic Goods Administration. Cosmetic injections checklist. 22 August 2019. URL: https://www.tga.gov.au/news/news-articles/cosmetic-injections-checklist
14. Therapeutic Goods Administration. Advertising health services and cosmetic injections: frequently asked questions and answers. Updated 10 July 2025. URL: https://www.tga.gov.au/products/regulations-all-products/advertising/specialised-advertising-issues-and-topics/advertising-health-services-and-cosmetic-injections-frequently-asked-questions-and-answers
15. NSW Health. Supply of prescription medicines. Updated 3 November 2025. URL: https://www.health.nsw.gov.au/pharmaceutical/Pages/legal-form-prescription.aspx
16. Queensland Health. Key legislative requirements – Medical practitioners. Queensland Health factsheet. URL: https://www.health.qld.gov.au/__data/assets/pdf_file/0014/1144310/fs-medical-practitioners.pdf
17. Queensland Health. Writing lawful prescriptions. Factsheet, current as at May 2026. URL: https://www.health.qld.gov.au/__data/assets/pdf_file/0011/1115003/writing-lawful-prescriptions.pdf
18. WA Department of Health. Requirements for prescriptions in Western Australia. URL: https://www.health.wa.gov.au/articles/a_e/dispensing-prescriptions/requirements-for-prescriptions-in-wa
19. WA Department of Health. Prescription record keeping requirements for pharmacists. URL: https://www.health.wa.gov.au/Articles/S_T/ScriptCheckWA/recording-keeping-requirements-for-pharmacists
20. Australian Health Practitioner Regulation Agency. Managing health records. URL: https://www.ahpra.gov.au/Resources/Managing-health-records.aspx
21. Office of the Australian Information Commissioner. Guide to health privacy. Published 9 May 2025. URL: https://www.oaic.gov.au/privacy/privacy-guidance-for-organisations-and-government-agencies/health-service-providers/guide-to-health-privacy
22. Australian Commission on Safety and Quality in Health Care. Making informed choices (Informed consent). Updated 27 March 2026. URL: https://www.safetyandquality.gov.au/your-rights/making-informed-choices-informed-consent
23. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Primary and Community Healthcare Standards. Updated 29 April 2026. URL: https://www.safetyandquality.gov.au/national-standards/national-safety-and-quality-primary-and-community-healthcare-standards
24. Australian Commission on Safety and Quality in Health Care. Primary and Community Healthcare Clinical Governance Standard. URL: https://www.safetyandquality.gov.au/national-standards/primary-and-community-healthcare-standards/primary-and-community-healthcare-clinical-governance-standard
25. Royal Australian College of General Practitioners. Management of type 2 diabetes: Summary of recommendations. Recommended as of 14 November 2024. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/management-of-type-2-diabetes/summary-of-recommendations
26. Royal Australian College of General Practitioners. Type 2 diabetes: Goals for optimum management. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/management-of-type-2-diabetes/type-2-diabetes-goals-for-optimum-management
27. Heart Foundation. 2023 Guideline for assessing and managing cardiovascular disease risk and Australian CVD risk calculator. URL: https://www.heartfoundation.org.au/for-professionals/guideline-for-managing-cvd
28. Nursing and Midwifery Board of Australia. Cosmetic injecting nurse banned. 7 January 2026. URL: https://www.nursingmidwiferyboard.gov.au/News/2026-01-07-Cosmetic-injecting-nurse-banned.aspx

This article is general regulatory and governance commentary, not legal advice.